Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
作者信息
Horiguchi Miki, Uno Hajime, Wei Lee-Jen
机构信息
Miki Horiguchi, Kitasato University School of Pharmacy, Tokyo, Japan; Hajime Uno, Dana-Farber Cancer Institute, Boston, MA; and Lee-Jen Wei, Department of Biostatistics, Harvard University, Boston, MA.
出版信息
J Clin Oncol. 2018 Mar 1;36(7):720-721. doi: 10.1200/JCO.2017.76.0983. Epub 2018 Jan 16.
PMID:29337638
Abstract
摘要
Zotero 插件